Orthofix Medical (NasdaqGS:OFIX) FY Conference Transcript

Summary of Orthofix Medical FY Conference Call Company Overview - Company: Orthofix Medical (NasdaqGS: OFIX) - Date of Conference: March 03, 2026 - Key Speakers: Matt Blackman (TD Cowen), Julie Andrews (CFO), Julie Dewey Key Points Company Positioning and Transformation - Orthofix inherited a company with strong assets but a weak operating model and financial profile, which were not conducive to sustainable growth [3][4] - The company underwent significant management and portfolio overhauls, focusing on financial health and operational efficiency [2][3] - The SeaSpine merger introduced innovation but also complexity and cash burn, necessitating a reset of the business foundation [3][4] Financial Performance and Growth Strategy - The company has shifted focus towards profitable growth, optimizing capital allocation and commercial footprint [6] - Over 75% of U.S. spine sales now come from the top 30 distributors, up from less than half in early 2024, leading to improved execution and predictability [6][16] - Debt refinancing in November 2024 improved liquidity and capital access, supporting long-term growth [7] - Orthofix has achieved eight consecutive quarters of EBITDA margin expansion, moving from a cash burn of over $100 million in 2023 to nearly breakeven in 2025 [8] Future Projections - The company targets a net sales CAGR of 6.5% to 7.5% from 2026 to 2028, with an adjusted EBITDA margin in the mid-teens by 2028 [22] - The growth will be driven by capturing benefits from distributor transitions, a strong innovation pipeline, and new product launches [27][28] Product Launches and Innovation - Orthofix plans over a dozen product launches in the next 18 months, including the Verata Open and Verata MIS platforms, which are expected to drive multi-year growth [7][28] - The company is also focusing on enhancing its Limb Reconstruction business, which has a significant market opportunity of $2.6 billion [88] Market Dynamics and Competitive Position - The Bone Growth Therapy (BGT) segment holds over 50% market share in the spine segment and is positioned for further growth in the fracture market, which is valued at approximately $250 million [60][67] - The Limb Reconstruction business is expected to return to double-digit growth, supported by new product launches and a focused commercial strategy [89] Challenges and Considerations - Legal expenses related to the former leadership team are expected to decrease, which has been a headwind for free cash flow [37][41] - The company is managing a 1% headwind in Q1 due to timing of utilization, but this is not expected to affect physician prescribing behavior [75][86] Conclusion - Orthofix is positioned for significant growth driven by operational improvements, a strong innovation pipeline, and a more efficient commercial strategy [52][112] - The company believes it is fundamentally stronger than two years ago, with a favorable outlook for future performance [112]